Rakovina Therapeutics Inc (TSE:RKV) has released an update.
Rakovina Therapeutics Inc. has successfully completed an oversubscribed private placement, raising $2 million to advance its cancer therapy research based on DNA-damage response technologies. The funds will be directed towards the company’s AI-driven drug candidate research, with expectations of initial data from in vivo models later in the year. This capital boost is intended to support the development of next-generation DDR drug candidates, aiming to enter human clinical trials in partnership with pharmaceutical companies.
For further insights into TSE:RKV stock, check out TipRanks’ Stock Analysis page.
